Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Theratechnologies Inc T.TH

Alternate Symbol(s):  THTX

Theratechnologies Inc. is a Canada-based clinical-stage biopharmaceutical company. The Company is focused on the development and commercialization of therapies addressing unmet medical needs. It markets prescription products for people with human immunodeficiency viruses (HIV) in the United States. The Company's research pipeline focuses on specialized therapies addressing unmet medical needs in HIV, nonalcoholic steatohepatitis (NASH) and oncology. Its medicines include Trogarzo and EGRIFTA SV (tesamorelin for injection). Trogarzo (ibalizumab-uiyk) injection is a long-acting monoclonal antibody which binds to domain 2 of the CD4 T cell receptors. EGRIFTA SV (tesamorelin for injection) is approved in the United States for the reduction of excess abdominal fat in people with HIV who have lipodystrophy. Its portfolio includes Phase I clinical trial of sudocetaxel zendusortide (TH1902), a novel peptide-drug conjugate (PDC), in patients with advanced ovarian cancer.


TSX:TH - Post by User

Comment by palinc2000on Feb 16, 2023 2:33pm
95 Views
Post# 35290444

RE:Interesting committee they've formed

RE:Interesting committee they've formed

Interesting group indeed but we should not expect those Committee members to spend much time on this ...They will review the data submitted by THTX and come up with opinions/ recommendations as to the path forward .... Hard to imagine that they can provide anything other than : try this try that have you thought about this and about that
It would be a lot more productive if there were a lot of data from which they could draw conclusions

Trials serve one purpose .... to prove or disprove 
I am of the opinion that the job ahead is humongous and for the sake of patients I hope that they can find a glimmer of hope sufficient to get a phama interested ..... That is the best we can hope for

Wino115 wrote: Very interesting group put together for this stage.

- The Yale doctor is the one who trialed docetaxal through all three phases for prostate cancer. So a specialist in what taxols can do. Hopefully he can also tap into that Yale PDC connection.  So he might be the chemo bomb expert.

- The Texas doctor (who's Canadian actually) specializes almost exclusively in doing Phase 1 trials for oncology. He also started a cancer genome project, so I assume he might be the expert around the target and sort1, maybe toxicity and safety issues to.  Also perhaps dosing logic.

- The Tennesee doctor seems to be a leader in gynecological and overall research, she seems to be a leader in the conferences and has a lot of social media followers. Seems sort of an all around type.

We know the lead investigator is the MD Anderson women along with those other 3-4 clinics and then Rothemberg sheparded 3-4 oncology drugs for Pfizer.  

Seems like they have the key bases covered. 

 

<< Previous
Bullboard Posts
Next >>